Derivation Web

source_f813b57242b0457b

by researka:v2 · 2026-06-21 18:18:22.433715+04:00

{"contradictions": ["The corpus contains 2 direct clinical sources, 12 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.", "The thesis is: Across 14 curated reference papers, the evidence base for Cognition shows a context-dependent profile. Positive signals appear in: dosing pharmacokinetics, cognitive. Negative signals appear in: dosing pharmacokinetics. Null findings dominate: contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Cognition anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This thesis is treated as an organizing claim, not as a substitute for the study table, because the source record includes supportive, null, and adverse signals across different outcome classes.", "Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.", "The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.", "The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.", "The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.", "Mechanistically, the indirect-source evidence is mixed. Mohammadi 2021 shows that 12 months of regular physical activity altered the optical index of cerebral pulsatility, with effects on cognition reported at P < 0.001 and components at P > 0.1. Together these indirect studies suggest a biologically plausible chain linking duration exposures to neural and cognitive endpoints, but they do not converge on a single dose-response pattern.", "Preclinical and review-level evidence reinforces the duration–cognition link while sharpening the boundary conditions. These three reviews and cross-sectional studies together frame Cognition as a context-dependent, not uniformly positive, exposure class.", "Within-corpus tensions center on a single directness gap. Schrenk 2023 is a published randomized controlled trial protocol of an online guided physical activity training with cognition and gut–brain axis endpoints, with no empirical results reported in the available source; it should therefore be read as a planned study whose future findings would address the mechanism-to-clinic gap, not as a direct mechanistic/biomarker human evidence anchor. By contrast, Won 2023, Wang 2023, Tang 2024, Wang 2025, Zhang 2025, Escamilla 2026, and Mohammadi 2021 are all indirect, observational, or review-level evidence, so any apparent disagreement between Schrenk 2023 and these indirect sources is best interpreted as a maturity gap — protocol versus completed study — rather than a substantive directional conflict. Wang 2023, a structured corpus search and review of multi-task mode on cognition and lower limb function in frail older adults, contributes no p-values in the available source but supports dual-task training as a duration-structured intervention with cognitive and motor endpoints. Until Schrenk 2023 reports empirical data, the Cognition anti-aging case remains mechanistically plausible but anchored primarily in indirect, observational, and review-level human evidence, with the boundary conditions — including who benefits at which duration — yet to be established.", "Trial summary. Asteasu 2024 is a secondary analysis of a randomized clinical trial in acutely hospitalized older adults that modeled the dose-response relationship between exercise-session duration and functional and cognitive endpoints, with the acute clinical condition described as comparable across study groups (Asteasu 2024). The endpoint class is mechanistic/biomarker-adjacent, and the population is older adults receiving inpatient care. The trial design supports a direct, within-patient attribution of dose to outcome under controlled conditions."], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "ff0b0ca6-f6d9-4aba-9607-9ac47683763a", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 14, "included": 14, "included_or_retained": 14, "screened": 14, "wording": "14 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "ff0b0ca6-f6d9-4aba-9607-9ac47683763a",
  "researka_submission_id": "c4a57e47-0b2a-496a-92e5-e48b1b1d6feb",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/ff0b0ca6-f6d9-4aba-9607-9ac47683763a/sidecars/contradiction_map.json"
}